In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma-Reference-Cited by-全球学者库

In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma

Published:2019-11-19 Issue:2 Volume:10 Page:270-287
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Li Fei,Huang Qingyuan,Luster Troy A.,Hu Hai,Zhang Hua,Ng Wai-Lung^ORCID,Khodadadi-Jamayran Alireza,Wang Wei,Chen Ting^ORCID,Deng Jiehui,Ranieri Michela,Fang Zhaoyuan,Pyon Val,Dowling Catríona M.,Bagdatlioglu Ece,Almonte Christina,Labbe Kristen,Silver Heather,Rabin Alexandra R.,Jani Kandarp,Tsirigos Aristotelis^ORCID,Papagiannakopoulos Thales,Hammerman Peter S.,Velcheti Vamsidhar,Freeman Gordon J.,Qi Jun,Miller George,Wong Kwok-Kin

Funder

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRISPRing KRAS: A Winding Road with a Bright Future in Basic and Translational Cancer Research;Cancers;2024-01-22

2. Prognostic value and potential mechanism of cellular senescence and tumor microenvironment in hepatocellular carcinoma: Insights from bulk transcriptomics and single‐cell sequencing analysis;Environmental Toxicology;2024-01-08

3. Exploiting the DNA Damage Response for Prostate Cancer Therapy;Cancers;2023-12-23

4. Applications of CRISPR screening to lung cancer treatment;Frontiers in Cell and Developmental Biology;2023-12-15

5. Unveiling immune checkpoint regulation: exploring the power of in vivo CRISPR screenings in cancer immunotherapy;Frontiers in Genetics;2023-12-14